Drug Profile
Halimide
Latest Information Update: 18 Jan 2008
Price :
$50
*
At a glance
- Originator Scripps Institution of Oceanography
- Developer Bristol-Myers Squibb; Scripps Institution of Oceanography
- Class Antineoplastics
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Jan 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 May 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 19 Nov 1998 New profile